Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mark W. Pierce"'
Autor:
Mark W. Pierce
Publikováno v:
Neurotherapeutics. 7:159-163
Migraine is a common, multisymptom disorder that can severely impact the daily activities of migraineurs. Triptans (primarily sumatriptan) are the most commonly prescribed treatment for migraine and are considered a relatively safe and effective init
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3b3eb53ae3507749afda7f22eff685d
https://doi.org/10.1016/j.nurt.2010.03.005
https://doi.org/10.1016/j.nurt.2010.03.005
Autor:
Aileen G. Hayes, Elizabeth Garofalo, John L. Arnett, Christina A Greeley, Carl B. Dodrill, Mark W. Pierce, Martha J Greiner
Publikováno v:
Epilepsy Research. 35:109-121
The cognitive and quality of life effects of gabapentin are not yet well explored. While preliminary work in the area has provided positive findings, a large double-blinded study has been needed to explore this area more thoroughly. From 24 sites in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b8fd29b8911af6381eb1056b8eb3c60
https://doi.org/10.1016/s0920-1211(99)00006-6
https://doi.org/10.1016/s0920-1211(99)00006-6
Autor:
Dale Kraemer, Margaret J. Knapp, James P. Symons, Richard DeJong, William G. Berghoff, Mark W Pierce, Sandra J. Lobbestael, Faye A. Luscombe, Stephen I. Gracon, Stuart L. Dombey
Publikováno v:
Alzheimer Disease & Associated Disorders. 12:93-101
The safety of tacrine (Cognex), a centrally active, reversible acetylcholinesterase inhibitor approved in 1993 for the treatment of mild to moderate dementia of the Alzheimer type, was evaluated in 2,706 patients with Alzheimer disease (AD) in clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2bbc1ec9cc9422b9f38612b98913b2b
https://doi.org/10.1097/00002093-199806000-00007
https://doi.org/10.1097/00002093-199806000-00007
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 20:407-417
1. Global improvement data from five double-blind clinical trials of gabapentin as add-on therapy in patients with epilepsy were reviewed to assess the effects of gabapentin on mood. 2. One hundred and ninety-four (46%) of 423 gabapentin-treated pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e10e92595368633e4fc9e41718360f36
https://doi.org/10.1016/0278-5846(96)00005-x
https://doi.org/10.1016/0278-5846(96)00005-x
Autor:
Stephen A. Cooper, Robert E. Pyke, Atul C. Pande, Mark W. Pierce, Ronald Benjamin, Martha Greiner
Publikováno v:
Clinical Neuropharmacology. 19:92-97
To study the analgesic efficacy of enadoline, a selective agonist of the kappa-opioid receptor, a double-blind, randomized comparison was made of enadoline versus placebo and a combination of acetaminophen-codeine in patients with pain after surgical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d1530570c3a8353dee542b890866f44
https://doi.org/10.1097/00002826-199619010-00009
https://doi.org/10.1097/00002826-199619010-00009
Publikováno v:
Epilepsy Research. 45:19-21
New drug development is best conceptualized as occurring in three phases: exploratory, registration, and commercialization. The most important initial goals in the exploratory phase of a new antiepileptic drug (AED) are to reliably determine efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b5b01bd4a31e1cf6f98326c9eac1e2a
https://doi.org/10.1016/s0920-1211(01)00207-8
https://doi.org/10.1016/s0920-1211(01)00207-8
Publikováno v:
Epilepsy Research. 45:129-131
The design of most add-on registration trials for anti epileptic drugs (AEDs) usually results in a calculated compromise regarding size, scope, cost, and duration. Appropriate trial duration incorporates issues such as efficacy, safety, and regulator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47019e779782e52a95d5ccaff9755eda
https://doi.org/10.1016/s0920-1211(01)00236-4
https://doi.org/10.1016/s0920-1211(01)00236-4
Publikováno v:
Biological Psychiatry. 46:860-862
Background: Based on the induction of panic-like symptoms by infusion of cholecystokinin (CCK) peptide in normals and panic disorder patients, it has been proposed that CCK may play a role in the disease mechanisms underlying anxiety disorders. Selec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b474d64aab643892de88f84f2c650f85
https://doi.org/10.1016/s0006-3223(99)00090-6
https://doi.org/10.1016/s0006-3223(99)00090-6
Publikováno v:
The American Journal of Medicine. 88:S12-S17
The safety profile of estazolam, a new triazolobenzodiazepine hypnotic medication, has been developed in 1,320 normal volunteers and patients with insomnia. No clinically significant effects of estazolam on vital signs or laboratory values were detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9324994550ab0628224555285438420
https://doi.org/10.1016/0002-9343(90)90280-q
https://doi.org/10.1016/0002-9343(90)90280-q
Autor:
Mark W. Pierce, Vincent S. Shu
Publikováno v:
The American Journal of Medicine. 88:S6-S11
The hypnotic efficacy of estazolam, a triazolobenzodiazepine, has been established in well-controlled sleep laboratory and outpatient clinical trials. Estazolam 1.0 mg and 2.0 mg significantly improves sleep latency, total sleep time, number of noctu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a61a5ced1fc80dfcdc12b338287db654
https://doi.org/10.1016/0002-9343(90)90279-m
https://doi.org/10.1016/0002-9343(90)90279-m